tiprankstipranks
Trending News
More News >
CG Oncology, Inc. (CGON)
NASDAQ:CGON
US Market
Advertisement

CG Oncology, Inc. (CGON) Stock Forecast & Price Target

Compare
173 Followers
See the Price Targets and Ratings of:

CGON Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
CG
Oncology, Inc.
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

CGON Stock 12 Month Forecast

Average Price Target

$60.57
▲(137.25% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for CG Oncology, Inc. in the last 3 months. The average price target is $60.57 with a high forecast of $82.00 and a low forecast of $41.00. The average price target represents a 137.25% change from the last price of $25.53.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"21":"$21","52":"$52","83":"$83","36.5":"$36.5","67.5":"$67.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":82,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$82.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$60.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$41.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[21,36.5,52,67.5,83],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.31,30.59384615384615,34.87769230769231,39.16153846153846,43.44538461538461,47.72923076923077,52.01307692307692,56.29692307692308,60.580769230769235,64.86461538461539,69.14846153846155,73.43230769230769,77.71615384615384,{"y":82,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.31,28.945384615384615,31.58076923076923,34.216153846153844,36.85153846153846,39.48692307692308,42.12230769230769,44.75769230769231,47.393076923076926,50.02846153846154,52.66384615384616,55.299230769230775,57.934615384615384,{"y":60.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.31,27.439999999999998,28.57,29.7,30.83,31.96,33.09,34.22,35.35,36.480000000000004,37.61,38.74,39.870000000000005,{"y":41,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":33.84,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.9,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.77,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.68,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.07,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.86,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.05,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.31,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$82.00Average Price Target$60.57Lowest Price Target$41.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on CGON
Piper Sandler
Piper Sandler
$55
Buy
115.43%
Upside
Initiated
08/18/25
CG Oncology initiated with an Overweight at Piper SandlerCG Oncology initiated with an Overweight at Piper Sandler
H.C. Wainwright Analyst forecast on CGON
H.C. Wainwright
H.C. Wainwright
$75
Buy
193.77%
Upside
Reiterated
08/11/25
CG Oncology's Strategic Advancements and Promising Data Reinforce Buy RatingHence, we reiterate that our Buy rating and $75.
LifeSci Capital Analyst forecast on CGON
LifeSci Capital
LifeSci Capital
$82
Buy
221.19%
Upside
Reiterated
08/08/25
Buy Rating for CG Oncology, Inc. Driven by Promising Clinical Data and Strategic Advancements
RBC Capital Analyst forecast on CGON
RBC Capital
RBC Capital
$53
Buy
107.60%
Upside
Reiterated
08/08/25
Wall Street Analysts Are Bullish on Top NA Picks
TD Cowen
Buy
Reiterated
08/08/25
Analysts Conflicted on These NA Names: Tempus AI, Inc. Class A (NASDAQ: TEM) and CG Oncology, Inc. (NASDAQ: CGON)We believe CG could report mature 24-month CRR at SUO in December 2025, where the potential mature 24- month CRR range is between 31% and 39%. Management has emphasized how strongly these AUA data have resonated with physicians, which is fueling enrollment into the company's other NMIBC trials. CG The BLA Ensuring A Broad Label Management plans to initiate the BLA submission process for creto in the Q4. Track designations should allow CG to use a rolling submission, similar to what JNJ did with TAR-200. To begin a rolling submission, the FDA requires upfront alignment on when information for each module is expected. While CG has clarity on the maturity of efficacy metrics, the company is conducting studies to streamline administration (2-step vs. 5-step) and validate creto's stability.
Bank of America Securities Analyst forecast on CGON
Bank of America Securities
Bank of America Securities
$63$62
Buy
142.85%
Upside
Reiterated
08/08/25
Bank of America Securities Sticks to Their Buy Rating for CG Oncology, Inc. (CGON)
Goldman Sachs Analyst forecast on CGON
Goldman Sachs
Goldman Sachs
Buy
Reiterated
07/18/25
We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.
Morgan Stanley Analyst forecast on CGON
Morgan Stanley
Morgan Stanley
$52$56
Buy
119.35%
Upside
Reiterated
06/17/25
CG Oncology price target raised to $56 from $52 at Morgan StanleyCG Oncology price target raised to $56 from $52 at Morgan Stanley
J.P. Morgan Analyst forecast on CGON
J.P. Morgan
J.P. Morgan
$41
Buy
60.60%
Upside
Reiterated
06/02/25
Promising Market Position and Investment Opportunity: CG Oncology's Creto in NMIBC Treatment
Scotiabank Analyst forecast on CGON
Scotiabank
Scotiabank
$23
Hold
-9.91%
Downside
Reiterated
05/14/25
Scotiabank Reaffirms Their Hold Rating on CG Oncology, Inc. (CGON)
Cantor Fitzgerald Analyst forecast on CGON
Cantor Fitzgerald
Cantor Fitzgerald
$75
Buy
193.77%
Upside
Reiterated
04/27/25
CG Oncology, Inc. (CGON) Gets a Buy from Cantor Fitzgerald
UBS
$60
Buy
135.02%
Upside
Initiated
10/24/24
CG Oncology initiated with a Buy at UBSCG Oncology initiated with a Buy at UBS
Roth MKM
$65
Buy
154.60%
Upside
Initiated
08/28/24
We initiate coverage of CG Buy rating and $65 price target. We anticipate share momentum as cretostimogene approaches a 2H25 BLA submission in BCG-unresponsive, high-risk non-muscle invasive bladder cancer (HR-NMIBC). We view cretostimogene's tolerability as a major differentiator, which could help gain market share from competitors that have tolerability issues in this setting. We believe promising cretostimogene efficacy bodes well for intermediate-risk NMIBC (IR-NMIBC). We see potential for $2B + in 2033 worldwide sales of creostimogene in BCG-unresponsive, HR- and IR-NMIBC.
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on CGON
Piper Sandler
Piper Sandler
$55
Buy
115.43%
Upside
Initiated
08/18/25
CG Oncology initiated with an Overweight at Piper SandlerCG Oncology initiated with an Overweight at Piper Sandler
H.C. Wainwright Analyst forecast on CGON
H.C. Wainwright
H.C. Wainwright
$75
Buy
193.77%
Upside
Reiterated
08/11/25
CG Oncology's Strategic Advancements and Promising Data Reinforce Buy RatingHence, we reiterate that our Buy rating and $75.
LifeSci Capital Analyst forecast on CGON
LifeSci Capital
LifeSci Capital
$82
Buy
221.19%
Upside
Reiterated
08/08/25
Buy Rating for CG Oncology, Inc. Driven by Promising Clinical Data and Strategic Advancements
RBC Capital Analyst forecast on CGON
RBC Capital
RBC Capital
$53
Buy
107.60%
Upside
Reiterated
08/08/25
Wall Street Analysts Are Bullish on Top NA Picks
TD Cowen
Buy
Reiterated
08/08/25
Analysts Conflicted on These NA Names: Tempus AI, Inc. Class A (NASDAQ: TEM) and CG Oncology, Inc. (NASDAQ: CGON)We believe CG could report mature 24-month CRR at SUO in December 2025, where the potential mature 24- month CRR range is between 31% and 39%. Management has emphasized how strongly these AUA data have resonated with physicians, which is fueling enrollment into the company's other NMIBC trials. CG The BLA Ensuring A Broad Label Management plans to initiate the BLA submission process for creto in the Q4. Track designations should allow CG to use a rolling submission, similar to what JNJ did with TAR-200. To begin a rolling submission, the FDA requires upfront alignment on when information for each module is expected. While CG has clarity on the maturity of efficacy metrics, the company is conducting studies to streamline administration (2-step vs. 5-step) and validate creto's stability.
Bank of America Securities Analyst forecast on CGON
Bank of America Securities
Bank of America Securities
$63$62
Buy
142.85%
Upside
Reiterated
08/08/25
Bank of America Securities Sticks to Their Buy Rating for CG Oncology, Inc. (CGON)
Goldman Sachs Analyst forecast on CGON
Goldman Sachs
Goldman Sachs
Buy
Reiterated
07/18/25
We resumed coverage of the Emerging Biotechnology sector last week, including 19 stocks, with Buy ratings on AMLX, AVBP, RNA, CGON, NBIX, RYTM, ROIV, and SNDX, and Sell ratings on ALT and GERN.
Morgan Stanley Analyst forecast on CGON
Morgan Stanley
Morgan Stanley
$52$56
Buy
119.35%
Upside
Reiterated
06/17/25
CG Oncology price target raised to $56 from $52 at Morgan StanleyCG Oncology price target raised to $56 from $52 at Morgan Stanley
J.P. Morgan Analyst forecast on CGON
J.P. Morgan
J.P. Morgan
$41
Buy
60.60%
Upside
Reiterated
06/02/25
Promising Market Position and Investment Opportunity: CG Oncology's Creto in NMIBC Treatment
Scotiabank Analyst forecast on CGON
Scotiabank
Scotiabank
$23
Hold
-9.91%
Downside
Reiterated
05/14/25
Scotiabank Reaffirms Their Hold Rating on CG Oncology, Inc. (CGON)
Cantor Fitzgerald Analyst forecast on CGON
Cantor Fitzgerald
Cantor Fitzgerald
$75
Buy
193.77%
Upside
Reiterated
04/27/25
CG Oncology, Inc. (CGON) Gets a Buy from Cantor Fitzgerald
UBS
$60
Buy
135.02%
Upside
Initiated
10/24/24
CG Oncology initiated with a Buy at UBSCG Oncology initiated with a Buy at UBS
Roth MKM
$65
Buy
154.60%
Upside
Initiated
08/28/24
We initiate coverage of CG Buy rating and $65 price target. We anticipate share momentum as cretostimogene approaches a 2H25 BLA submission in BCG-unresponsive, high-risk non-muscle invasive bladder cancer (HR-NMIBC). We view cretostimogene's tolerability as a major differentiator, which could help gain market share from competitors that have tolerability issues in this setting. We believe promising cretostimogene efficacy bodes well for intermediate-risk NMIBC (IR-NMIBC). We see potential for $2B + in 2033 worldwide sales of creostimogene in BCG-unresponsive, HR- and IR-NMIBC.
Stocks with the Highest Top Analyst Consensus in the General Sector
Find stocks in the General sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering CG Oncology, Inc.

1 Month
xxx
Success Rate
4/7 ratings generated profit
57%
Average Return
+0.07%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +0.07% per trade.
3 Months
xxx
Success Rate
3/7 ratings generated profit
43%
Average Return
-6.54%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of -6.54% per trade.
1 Year
Success Rate
3/7 ratings generated profit
43%
Average Return
-3.94%
reiterated a buy rating 15 days ago
Copying Tyler Van Buren's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of -3.94% per trade.
2 Years
xxx
Success Rate
3/7 ratings generated profit
43%
Average Return
-3.94%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 42.86% of your transactions generating a profit, with an average return of -3.94% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

CGON Analyst Recommendation Trends

Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
14
18
14
11
11
Buy
3
4
4
5
4
Hold
5
11
13
14
12
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
33
31
30
27
In the current month, CGON has received 15 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. CGON average Analyst price target in the past 3 months is 60.57.
Each month's total comprises the sum of three months' worth of ratings.

CGON Financial Forecast

CGON Earnings Forecast

Next quarter’s earnings estimate for CGON is -$0.56 with a range of -$0.63 to -$0.47. The previous quarter’s EPS was -$0.54. CGON beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.02% of the time in the same period. In the last calendar year CGON has Outperformed its overall industry.
Next quarter’s earnings estimate for CGON is -$0.56 with a range of -$0.63 to -$0.47. The previous quarter’s EPS was -$0.54. CGON beat its EPS estimate 25.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.02% of the time in the same period. In the last calendar year CGON has Outperformed its overall industry.

CGON Sales Forecast

Next quarter’s sales forecast for CGON is $82.00K with a range of $0.00 to $600.00K. The previous quarter’s sales results were $0.00. CGON beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 53.92% of the time in the same period. In the last calendar year CGON has Outperformed its overall industry.
Next quarter’s sales forecast for CGON is $82.00K with a range of $0.00 to $600.00K. The previous quarter’s sales results were $0.00. CGON beat its sales estimates 25.00% of the time in past 12 months, while its overall industry beat sales estimates 53.92% of the time in the same period. In the last calendar year CGON has Outperformed its overall industry.

CGON Stock Forecast FAQ

What is CGON’s average 12-month price target, according to analysts?
Based on analyst ratings, CG Oncology, Inc.’s 12-month average price target is 60.57.
    What is CGON’s upside potential, based on the analysts’ average price target?
    CG Oncology, Inc. has 137.25% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is CGON a Buy, Sell or Hold?
          CG Oncology, Inc. has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is CG Oncology, Inc.’s price target?
            The average price target for CG Oncology, Inc. is 60.57. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $82.00 ,the lowest forecast is $41.00. The average price target represents 137.25% Increase from the current price of $25.53.
              What do analysts say about CG Oncology, Inc.?
              CG Oncology, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of CGON?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis